GSK's experimental drug for asthma met its goals in the latest trial, moving a treatment with potential annual peak sales of more than $3.81 billion closer to market.

GSK’s experimental drug for asthma met its goals in the latest trial, moving a treatment with potential annual peak sales of more than $3.81 billion closer to market.